Regulation of Chondrocyte Metabolism and Osteoarthritis Development by Sirt5 Through Protein Lysine Malonylation
Arthritis & Rheumatology · 2025
DOI: 10.1002/art.43164 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, 2025. Verfasst von Huanhuan Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Heritage College of Osteopathic Medicine, Ohio University, Athens. Hauptthemen laut MEDLINE: Chondrocytes, Sirtuins, Osteoarthritis, Lysine. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIH HHS, NIAMS NIH HHS, Arthritis National Research Foundation.
Abstract (Originalsprache)
Objective
Chondrocytemetabolic dysfunction plays an important role in osteoarthritis (OA) development during aging and obesity. Protein posttranslational modifications (PTMs) have recently emerged as an important regulator of cellular metabolism. We aim to study one type of PTM, lysine malonylation (MaK), and its regulator sirtuin 5 (Sirt5) in OA development.
Methods
Human and mouse cartilage tissues were used to measure SIRT5 and MaK levels. Both systemic and cartilage‐specific conditional knockout mouse models were subject to high‐fat diet treatment to induce obesity and OA. Proteomics analysis was performed in Sirt5 −/− and wild‐type chondrocytes. SIRT5 mutation was identified in the Utah Population Database.
Results
We found that SIRT5 decreases while MaK increases in the cartilage during aging. A combination of Sirt5 deficiency and obesity exacerbates joint degeneration in a sex‐dependent manner in mice. We further delineate the malonylome in chondrocytes, pinpointing MaK's predominant impact on various metabolic pathways, such as carbon metabolism and glycolysis. Lastly, we identified a rare coding mutation in SIRT5 that dominantly segregates in a family with OA. The mutation results in substitution of an evolutionally invariant phenylalanine to leucine (F101L) in the catalytic domain. The mutant protein results in a higher MaK level and decreased expression of cartilage extracellular matrix genes and upregulation of inflammation‐associated genes.
Conclusion
We found that Sirt5‐mediated MaK is an important regulator of chondrocyte cellular metabolism, and dysregulation of Sirt5‐MaK could be an important mechanism underlying aging‐ and obesity‐associated OA development. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Heritage College of Osteopathic Medicine, Ohio University, Athens.
- University of Bradford, Bradford, University of Exeter, Exeter, United Kingdom.
- University of Utah, Salt Lake City.
- Buck Institute for Research on Aging, Novato, California.
ORCID-Profile: Michael J Jurynec, Shouan Zhu
Förderung
- NIH HHS
- NIAMS NIH HHS
- Arthritis National Research Foundation
- American Society for Bone and Mineral Research
- Rheumatology Research Foundation
- Hevolution Foundation
- National Institutes of Health
Zitieren
APA
Liu, H., Binoy, A., Ren, S., Martino, T. C., Miller, A. E., Willis, C. R. G., Veerabhadraiah, S. R., Bons, J., Rose, J. P., Schilling, B., Jurynec, M. J., & Zhu, S. (2025). Regulation of Chondrocyte Metabolism and Osteoarthritis Development by Sirt5 Through Protein Lysine Malonylation. Arthritis & Rheumatology. https://doi.org/10.1002/art.43164
Vancouver
Liu H, Binoy A, Ren S, Martino TC, Miller AE, Willis CRG, et al. Regulation of Chondrocyte Metabolism and Osteoarthritis Development by Sirt5 Through Protein Lysine Malonylation. Arthritis & Rheumatology. 2025. doi:10.1002/art.43164
BibTeX
@article{Liu2025,
author = {Liu, Huanhuan and Binoy, Anupama and Ren, Siqi and Martino, Thomas C and Miller, Anna E and Willis, Craig R G and Veerabhadraiah, Shivakumar R and Bons, Joanna and Rose, Jacob P and Schilling, Birgit and Jurynec, Michael J and Zhu, Shouan},
title = {Regulation of Chondrocyte Metabolism and Osteoarthritis Development by Sirt5 Through Protein Lysine Malonylation},
journal = {Arthritis & Rheumatology},
year = {2025},
doi = {10.1002/art.43164}
}
EUVIMED